Nuvation Bio Inc Warrants
NUVB.WS
NUVB.WS was delisted on the 10th of February, 2026.
19 hedge funds and large institutions have $14.7M invested in Nuvation Bio Inc Warrants in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 5 reducing their positions, and 3 closing their positions.
0.07% less ownership
Funds ownership: 1.91% → 1.84% (-0.07%)
14% less funds holding
Funds holding: 22 → 19 (-3)
22% less capital invested
Capital invested by funds: $18.8M → $14.7M (-$4.09M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$242K |
| 2 |
CC
Clearline Capital
New York
|
-$85K |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$68K |
| 4 |
BlackRock
New York
|
-$4.91K |
| 5 |
IP
Intellectus Partners
San Francisco,
California
|
-$3.02K |
NUVB.WS Hedge Fund Activity: Q4 2021 in Review
19 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio Inc Warrants (NUVB.WS) for Q4 2021, worth a combined $14.7M — down 22% from $18.8M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NUVB.WS and 0 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 0 added.
The largest seller was Acuta Capital Partners, exiting entirely with an estimated $242K sold.
- 19 institutional investors held Nuvation Bio Inc Warrants (NUVB.WS) as of Q4 2021, down from 22 in Q3 2021.
- Funds reported $14.7M of Nuvation Bio Inc Warrants stock for Q4 2021, down 22% quarter-over-quarter.
- 0 funds opened new Nuvation Bio Inc Warrants positions in Q4 2021 and 3 closed out, a net change of -3 holders.
- The largest Nuvation Bio Inc Warrants seller in Q4 2021 was Acuta Capital Partners, an estimated $242K sold.
Based on aggregated 13F filings for Q4 2021.